Refractory Cancer clinical trials

Explore recruiting refractory cancer clinical trials.

Recruiting refractory cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Intrathecal drug delivery systems versus comprehensive medical management for severe cancer pain: a randomized controlled trial

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability, and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study)

Belgium, France, Spain, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Refractory Cancer trials by city

Refractory Cancer in Toronto Refractory Cancer in Vancouver Refractory Cancer in Montreal Refractory Cancer in Calgary Refractory Cancer in Edmonton Refractory Cancer in Ottawa Refractory Cancer in Winnipeg Refractory Cancer in Quebec City Refractory Cancer in Hamilton Refractory Cancer in Kitchener Refractory Cancer in London Refractory Cancer in Halifax Refractory Cancer in New York Refractory Cancer in Los Angeles Refractory Cancer in Chicago Refractory Cancer in Houston

Refractory Cancer clinical trials

Recruiting refractory cancer studies right now

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

CAR-T Followed by Bispecific Antibodies

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Also recruiting in Europe

Intrathecal drug delivery systems versus comprehensive medical management for severe cancer pain: a randomized controlled trial

A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability, and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study)

Refractory Cancer trials by city

Other conditions